Quarterly Activity Report and Appendix C
Imagion Biosystems has released their Quarterly Activity Report for the period ended 30 September 2020 and Appendix C. Q3 Highlights Raised $4.7M (after…
Imagion Biosystems Appoints Geoff Hollis as CFO
Imagion Biosystems has appointed Geoff Hollis as Chief Financial Officer. The appointment strengthens the Company’s management and leadership team as the…
HREC Approval for Phase I Study
Imagion Biosystems is pleased to report that it has received approval from the Human Research Ethics Committee (HREC) for the MagSense® HER2 Phase I study…
CEO Bob Proulx Featured on Biotech2050 Podcast
Earlier this year Imagion Biosystems CEO Bob Proulx was invited to be a guest and record an episode of the Biotech2050 podcast. The COVID-19 pandemic delayed…
Appendix 4D and Half Year Results H1 2020
Imagion Biosystems has announced Appendix 4D and Half Year Results H1 2020. These are the highlights: Significant advancements towards initiating…
IBX Secures Additional Capital — Shareholders Exercise Options
Imagion Biosystems Limited announce that it has received $1.29m for the exercise of unlisted options issued under the terms of the 2018 Rights Issue…
Phase I Study Update: Submission for Ethics Approval Filed
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense® product for the detection of…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000…
Quarterly Activity Report and Appendix C
Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…
Proposed Issue of Securities — IBX
Imagion Biosystems Limited has announced a Proposed Issue of Securities. Read the Proposed Issue of Securities.